CVM250117C1500
- 0.05
- 0.000.00%
CEL-SCI Newsroom
CEL-SCI Completes $5 Million 'Best Efforts' Stock Sale
12 Health Care Stocks Moving In Monday's Pre-Market Session
Crude Oil Gains 1%; Chicago PMI Falls In December
US Stocks Open Lower; Dow Tumbles 600 Points
What's Going On With Cel-Sci Shares Premarket On Monday?
Why Vincerx Pharma Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket
CCSC Technology International, CEL-SCI And 3 Stocks To Watch Heading Into Monday
CEL-SCI Announces Proposed Public Offering of Common Stock
Express News | Amex Halt Add Info Lst 0.840000
CEL-SCI Announced Multikine Demonstrates Tumor Regression Pre-Surgery In 3 Weeks; FDA Approves 212-Person Study With 73% Survival Rate Vs. 45% Control In Head And Neck Cancer
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
Watching CEL-SCI; Zacks Small-Cap Research Gives Stock $7 Price Valuation
Express News | CEL-SCI Corp: On November 13, Patricia B Prichep Has Assumed the Duties of Chief Financial and Operations Officer
CEL-SCI, FDA Agree on Phase 3 Trial Design for Cancer Drug
U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025
Express News | CEL-SCI Corp Files Prospectus Relates to Possible Resale, From Time to Time, by Selling Shareholder of up to 1 Mln Shares of Common Stock
CEL-SCI Announces The Potential Impact On The Clinical Development Of Its Immunotherapy Multikine Resulting From A Recent U.S. FDA Oncologic Drugs Advisory Committee Meeting; Multikine Has Shown Survival Benefit And Favorable Safety Profile In A...
FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
CEL-SCI Selects Ergomed as CRO as It Gears Up for Confirmatory FDA Registration Study of Multikine in Head and Neck Cancer
CEL-SCI to Present New Data for Multikine Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress